Overview

A Study on the Timing of FOLFOX for Patients With Operable, Node Positive Rectal Cancer

Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This study is proposed to evaluate whether giving part of the chemotherapy prior to radiotherapy and surgery (as opposed to standard of care, which involves giving all the chemotherapy after radiotherapy and surgery) for patients with node positive operable rectal cancer will result in higher patient compliance to chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Sir Mortimer B. Davis - Jewish General Hospital
Collaborator:
Sanofi